Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement - S. vander Veer, Marc Vervloet, D. Goldsmith, A. Covic, V. Brandenburg, David Goldsmith, M. Vervloet, J. Bover, Chronic Kidney Disease-Mineral Bone Disease, P. Evenepoel, M. Cozzolino, Z. Massy, S. Mazzaferro, Ionut Nistor, Adrian Covic - Dissemin

Language
Login

Published in

Oxford University Press (OUP), Nephrology Dialysis Transplantation, 5(30), p. 698-700

DOI: 10.1093/ndt/gfv050

Links

Tools

Export citation

Search in Google Scholar

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

Journal article published in 2015 by S. vander Veer, Marc Vervloet, D. Goldsmith, A. Covic, V. Brandenburg, David Goldsmith, M. Vervloet, J. Bover, Chronic Kidney Disease-Mineral Bone Disease, P. Evenepoel, M. Cozzolino, Z. Massy, S. Mazzaferro, Ionut Nistor, Adrian Covic and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO